The COVID-19 pandemics and the relevance of biosafety facilities for metagenomics surveillance, structured disease prevention and control

dc.creatorSouza, Thiago Moreno L.
dc.creatorMorel, Carlos Medicis
dc.date2022-04-30T23:21:50Z
dc.date2022-04-30T23:21:50Z
dc.date2021
dc.date.accessioned2023-09-26T23:18:21Z
dc.date.available2023-09-26T23:18:21Z
dc.identifierSOUZA, Thiago Moreno Lopes; MOREL, Carlos Medicis. The COVID-19 pandemics and the relevance of biosafety facilities for metagenomics surveillance, structured disease prevention and control. Biosafety and Health, v. 3, p. 1-3, 2021.
dc.identifier2590-0536
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/52484
dc.identifier10.1016/j.bsheal.2020.11.007
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8889102
dc.descriptionSince January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
dc.descriptionWe thank David William Provance Jr., Fiocruz/CDTS, for his careful final revision of the manuscript. Thisworkwas supported byCNPq (ConselhoNacional de Desenvolvimento Científico e Tecnológico), FAPERJ (Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro) through grants received by TMLS. Funding was also provided by CNPq, CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior) and FAPERJ through the National Institutes of Science and Technology Program (INCT) to CMM (INCT-IDPN). Thanks are due to Oswaldo Cruz Foundation/FIOCRUZ under the auspicious of Inova program (B3- Bovespa funding). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
dc.descriptionThe coronavirus disease 2019 (COVID-19) pandemic represents an enormous challenge to all countries, regardless of their development status. The manipulation of its etiologic agent SARS-CoV-2 requires a biosafety containment level 3 laboratories (BSL-3) to understand virus biology and in vivo pathogenesis as well as the translation of new knowledge into the preclinical development of vaccines and antivirals. As such, BSL-3 facilities should be considered an integral part of any public health response to emerging infectious disease prevention, control and management. Differently from BSL-2, BSL-3 units vary considerably along the range from industrialized to the least developed countries. Innovative Developing Countries (IDCs) such as Brazil, which excelled at controlling the 2015–2017 Zika epidemic, had to face a serious flaw in its disease control and prevention structure: the scarcity and uneven geographic distribution of its BSL-3 facilities, including those for preclinical animal experimentation.
dc.formatapplication/pdf
dc.languageeng
dc.publisherElsevier
dc.relationhttps://www.arca.fiocruz.br/handle/icict/44921
dc.rightsopen access
dc.subjectSARS-CoV-2
dc.subjectCOVID-19
dc.subjectBiosafety facilities
dc.subjectInnovative Developing Countries (IDCs)
dc.subjectMetagenomics surveillance
dc.titleThe COVID-19 pandemics and the relevance of biosafety facilities for metagenomics surveillance, structured disease prevention and control
dc.typeArticle


Este ítem pertenece a la siguiente institución